Central Acceptance Testing for Camera Technologies for CTA

The Cherenkov Telescope Array (CTA) is an international initiative to build the next generation ground based very-high energy gamma-ray observatory. It will consist of telescopes of three different sizes, employing several different technologies for the cameras that detect the Cherenkov light from the observed air showers. In order to ensure the compliance of each camera technology with CTA requirements, CTA will perform central acceptance testing of each camera technology. To assist with this, the Camera Test Facilities (CTF) work package is developing a detailed test program covering the most important performance, stability, and durability requirements, including setting up the necessary equipment. Performance testing will include a wide range of tests like signal amplitude, time resolution, dead-time determination, trigger efficiency, performance testing under temperature and humidity variations and several others. These tests can be performed on fully-integrated cameras using a portable setup at the camera construction sites. In addition, two different setups for performance tests on camera sub-units are being built, which can provide early feedback for camera development. Stability and durability tests will include the long-term functionality of movable parts, water tightness of the camera housing, temperature and humidity cycling, resistance to vibrations during transport or due to possible earthquakes, UV-resistance of materials and several others. Some durability tests will need to be contracted out because they will need dedicated equipment not currently available within CTA. The planned test procedures and the current status of the test facilities will be presented.Comment: 8 pages, 3 figures. In Proceedings of the 34th International Cosmic Ray Conference (ICRC2015), The Hague, The Netherlands. All CTA contributions at arXiv:1508.0589

Rapid and efficient stable gene transfer to mesenchymal stromal cells using a modified foamy virus vector

Mesenchymal stromal cells (MSCs) hold great promise for regenerative medicine. Stable ex vivo gene transfer to MSCs could improve the outcome and scope of MSC therapy, but current vectors require multiple rounds of transduction, involve genotoxic viral promoters and/or the addition of cytotoxic cationic polymers in order to achieve efficient transduction. We describe a self-inactivating foamy virus vector (FVV), incorporating the simian macaque foamy virus envelope and using physiological promoters, which efficiently transduces murine MSCs (mMSCs) in a single-round. High and sustained expression of the transgene, whether GFP or the lysosomal enzyme, arylsulphatase A (ARSA), was achieved. Defining MSC characteristics (surface marker expression and differentiation potential), as well as long-term engraftment and distribution in the murine brain following intracerebroventricular delivery, are unaffected by FVV transduction. Similarly, greater than 95% of human MSCs (hMSCs) were stably transduced using the same vector, facilitating human application. This work describes the best stable gene transfer vector available for mMSCs and hMSCs

Sub-wavelength surface IR imaging of soft-condensed matter

Outlined here is a technique for sub-wavelength infrared surface imaging performed using a phase matched optical parametric oscillator laser and an atomic force microscope as the detection mechanism. The technique uses a novel surface excitation illumination approach to perform simultaneously chemical mapping and AFM topography imaging with an image resolution of 200 nm. This method was demonstrated by imaging polystyrene micro-structures

Cell therapy for autoimmune diseases

Cell therapy, pioneered for the treatment of malignancies in the form of bone marrow transplantation, has subsequently been tested and successfully employed in autoimmune diseases. Autologous haemopoietic stem cell transplantation (HSCT) has become a curative option for conditions with very poor prognosis such as severe forms of scleroderma, multiple sclerosis, and lupus, in which targeted therapies have little or no effect. The refinement of the conditioning regimens has virtually eliminated transplant-related mortality, thus making HSCT a relatively safe choice. Although HSCT remains a nonspecific approach, the knowledge gained in this field has led to the identification of new avenues. In fact, it has become evident that the therapeutic efficacy of HSCT cannot merely be the consequence of a high-dose immuno-suppression, but rather the result of a resetting of the abnormal immune regulation underlying autoimmune conditions. The identification of professional and nonprofessional immunosuppressive cells and their biological properties is generating a huge interest for their clinical exploitation. Regulatory T cells, found abnormal in several autoimmune diseases, have been proposed as central to achieve long-term remissions. Mesenchymal stem cells of bone marrow origin have more recently been shown not only to be able to differentiate into multiple tissues, but also to exert a potent antiproliferative effect that results in the inhibition of immune responses and prolonged survival of haemopoietic stem cells. All of these potential resources clearly need to be investigated at the preclinical level but support a great deal of enthusiasm for cell therapy of autoimmune diseases